anthracyclines – Medxy AI

High-Sensitivity Troponin I: A Poor Predictor of Anthracycline-Induced Left Ventricular Dysfunction?

By MedXY 12/25/2025

The Cardiac CARE trial reveals that high-sensitivity cardiac troponin I levels do not correlate with cumulative anthracycline dose and only weakly predict subsequent declines in left ventricular function, challenging existing risk-stratification models in cardio-oncology.

Cardiology news Oncology

Sacubitril-Valsartan Prevents Anthracycline-Induced Myocardial Dysfunction: Results from the SARAH Trial

By MedXY 12/24/2025

The SARAH trial demonstrates that sacubitril-valsartan significantly reduces subclinical left ventricular dysfunction in patients with elevated troponin during anthracycline chemotherapy, potentially offering a new cardioprotective strategy for high-risk oncology patients.

Cardiology news Oncology

Long-Term Risk Factors for Valvular Heart Disease in Childhood Cancer Survivors: Insights from a European Case-Control Study

By MedXY 10/10/2025

Heart radiation, anthracyclines, and platinum chemotherapy significantly increase the risk of valvular heart disease decades after childhood cancer treatment, highlighting the need for vigilant, lifelong cardiac monitoring in survivors.